SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Abstract connected lines and dots/iStock
Insilico CEO Alex Zhavoronkov Discusses AI Drug Discovery
The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology.
January 17, 2024
 · 
3 min read
 · 
Tyler Patchen
Facade of the FDA's office in Maryland
FDA
FDA Approves Vertex, CRISPR’s Casgevy to Treat Beta Thalassemia
Vertex Pharmaceuticals and CRISPR Therapeutics have secured another FDA approval for their Casgevy Cas9 gene-edited cell therapy, this time in treating transfusion-dependent beta thalassemia.
January 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Disco ball with bright rays/iStock
Business
AbbVie-Backed Disco Launches with $20M in Funding, Targets Oncology
Disco Pharmaceuticals is taking to the biotech dance floor with seed funding from major players and pipeline programs in small cell lung cancer and colorectal cancer.
January 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: San Francisco with text overlay/Taylor T
Deals
7 Deals Emerge During JPM Week in Strong Start to 2024
Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
January 15, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: An Eli Lilly Research Laboratories sign/
JPM2024: Lilly CEO David Ricks Weighs In on GLP-1s and AI
As JPM week draws close, Lilly CEO David Ricks talks about what he thinks is in store for the biopharma industry.
January 12, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Takeda Pharmaceutical sign/iStock, jetci
Business
Q&A: Takeda’s Elena Koundourakis Talks Orexin Program Ahead of Expected Readout
Speaking to BioSpace in San Francisco, Elena Koundourakis, the head of the orexin franchise at Takeda Pharmaceuticals, gave a preview of what is ahead for its aims to treat narcolepsy.
January 11, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: San Francisco’s Union Square/iStock, tra
JPM2024: Cancer Biotech Executives Look Ahead to the Coming Year
A lot of attention at JPM was focused on the cancer space. Executives from Olema Oncology and Cyclacel spoke with BioSpace about their plans for 2024 and why biotech’s kickoff conference is important to them.
January 11, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A sign for Manhattan’s Wall Street with
Deals
‘Let The Good Times Roll Again’: VCs Confident in Biotech Activity for ’24
Panelists at JPM’s Biotech Showcase gave positive projections as the year begins and offered advice to those in the space.
January 11, 2024
 · 
2 min read
 · 
Tyler Patchen
Deals
Listen: JPM2024 Day 3 Highlights
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.
January 10, 2024
 · 
1 min read
 · 
Lori Ellis
BCG Panel: ‘No Single Approach’ to Maximizing Generative AI in Biotech and Healthcare
For experts on Boston Consulting Group’s generative AI panel, effectively using the technology in the biotech industry will be a collaborative process.
January 10, 2024
 · 
2 min read
 · 
Tyler Patchen
3d render of cytotoxic CAR exosomes secreted by engineered T immune cells
Business
FDA’s CAR T Probe ‘Not a Big Deal’ for Oncology-Focused Biotechs: Triumvira President
Triumvira Immunologics’ president and chief operating officer Rob Williamson noted that cell therapy companies might still have an uphill battle unless they can differentiate.
January 10, 2024
 · 
2 min read
 · 
Tyler Patchen
Drug Development
Listen: JPM2024 Day 2 Highlights
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.
January 9, 2024
 · 
1 min read
 · 
Lori Ellis
Neurosurgeon analyzes an MRI, iStock, gorodenkoff
AI, Neuroscience and GLP-1s Will Maintain Momentum: Expert Panel
As the second day of the 42nd J.P. Morgan Healthcare Conference dawned in San Francisco, experts from Boston Consulting Group, Merck, CVC and more provided their outlook on the year ahead.
January 9, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A nasal vaccine being administered to a
JPM2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development
The executive spoke with Biospace about Codagenix’s nasal COVID-19 spray vaccine, the COVID market, and how the company fits into the broader infectious disease space.
January 9, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: A Canada-U.S. Border Crossing_iStock, eh
Policy
FDA Gives the OK for Florida to Import Drugs from Canada
The state must submit additional information about the drugs it intends to import before the first shipments are sent to the U.S.
January 7, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More